from the ah,-patents dept
That's a bit of interesting background for the fact that the Italian antitrust authority recently found drug giant Pfizer guilty of abusing antitrust law in the country to try to delay or block competition from generic drugs. According to the report linked here, Pfizer was specifically called out on two points:
1. the artificial extension of the Xalatan patent in Italy by means of: a) the application of a divisional patent; b) the validation of the divisional patent in Italy; c) the application for an SPC in Italy; d) the application for pediatric extension; andPfizer is expected to appeal, and the blog post linked here (from law firm DLA Piper) suggests that it has a decent chance of having the original ruling reversed. But, really, that's quite a change in just a few decades. From being a leader in the market -- often by building on the ability to produce generics -- to one where cheaper generics (which help keep people healthy in a more affordable way) are aggressively blocked from the market by activities of giant multinational pharma companies.
2. the start of litigations aimed at discouraging or increasing the costs for the marketing of latanoprost generic products in Italy.